KR920703134A - 생유기체의 생물부, 특히 기관을 생성하기 위한 활성물질 복합체, 이를 제조하는 방법 및 이의 용도 - Google Patents

생유기체의 생물부, 특히 기관을 생성하기 위한 활성물질 복합체, 이를 제조하는 방법 및 이의 용도

Info

Publication number
KR920703134A
KR920703134A KR1019920701038A KR920701038A KR920703134A KR 920703134 A KR920703134 A KR 920703134A KR 1019920701038 A KR1019920701038 A KR 1019920701038A KR 920701038 A KR920701038 A KR 920701038A KR 920703134 A KR920703134 A KR 920703134A
Authority
KR
South Korea
Prior art keywords
growth factor
active material
active substance
complex
components
Prior art date
Application number
KR1019920701038A
Other languages
English (en)
Other versions
KR100195549B1 (ko
Inventor
슈미트 칼하인츠
Original Assignee
슈미트 칼하인츠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈미트 칼하인츠 filed Critical 슈미트 칼하인츠
Publication of KR920703134A publication Critical patent/KR920703134A/ko
Application granted granted Critical
Publication of KR100195549B1 publication Critical patent/KR100195549B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Prostheses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

생유기체의 생물부, 특히 기관을 생성하기 위한 활성물질 복합체, 이를 제조하는 방법 및 이의 용도
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 구조적 성분; 하나 이상의 점증화(recruiting)성분; 하나 이상의 유착(adhesion)성본; 및 하나 이상의 성분 및/또는 성숙 성분(바람직하게는 하나 이상의 사이토킨 형태)로을 포함하는 생유기체의 생물부(biological part)의 생성, 특히 기관의 생성을 위한 활성물질 복합체(active substance complex).
  2. 제1항에 있어서, 구조적 성분이 바람직하게는 프로테오글리칸 및 콜라겐의 거대분자성 겔 및/또는 네트워크(network)인 활성물질 복합체.
  3. 제1항 또는 제2항에 있어서, 구조적 성분이 고체 및/또는 유공 형태 및/또는 막 형태 및/또는 교질입자 형태 및/또는 가소적 변형 형태 및/또는 점성 형태 및/또는 액체 형태중에, 금속성 지지체 물질 및/또는, 세라믹성 지지체 물질 및/또는, 초자성 지지체 물질 및/또는, 중합체성 지지체 물질 및/또는 지방성 지지체 물질을 갖는 활성물질 복합체.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 관련 점증화 성분이 화학주성 펩타이드, 단백질 및/또는 아리키돈산 대사물 및 이의 혼합물로 구성된 그룹중에서 선택되는 활성물질 복합체.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 관련 유착 성분이 피브로넥틴, 테나신, 사이토탁틴, 라미닌, 콘드로넥틴, 콜라겐 타입 IV, V, VII, N-CAM, L-CAM 또는 인터그린 및 상기 단백질들의 배합물로 구성된 그룹중에서 선택되는 단백질인 활성물질 복합체.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, 관련 성장 및/또는 성숙 성분이 콜로니-자극성 인자(CSF), 인터루킨(IL), 인슐린-유사 성장 인자(IGF), 프로스타글란딘(PG), 류코트린(LT), 변형 성장 인자(TGF), 섬유아세포 성장 인자(FGF), 인터페론(IFN), 상피 성장 인자(EGF), 뼈로부터 유래된 성장인자(BDGF), 내피로부터 유래된 성장인자(EDGF), 전구로부터 유래된 성장인자(PDGF) 및 이러한 인자들의 배합물로 구성된 구룹중에서 선택되는 활성물질 복합체.
  7. 제1항 내지 제6항중 어느 한 항에 있어서, 관련 성장 및/또는 성숙인자가 혈관의 가속된 성장을 위한 인자(예:맥관형성 인자) 및/또는 신경의 가속된 성장을 위한 인자(예:신경 성장인자)를 생성되는 생물부중에 포함하는 활성물질 복합체.
  8. 제1항 내지 제7항중 어느 한 항에 있어서, (효소)억제제 및/또는 면역억제성 및/또는 염증-억제 성분을 포함함을 특징으로 하는, 구조적 성분의 가교결합의 분해 속도를 상이한 정도로 조절하는 수단을 추가로 포함하는 활성물질 복합체.
  9. 제1항 내지 제8항중 어느 한 항에 있어서, 적어도 동일한 합성 단계에서 표적 세포와 함께 생물부를 형성하는 활성물질 복합체.
  10. 활성물질 복합체를 동결건조에 의해 상이한 성분의 혼합된 침전으로 생성시킬 수 있는, 제1항 내지 제9항중 어느 한 항에 따른 활성물질 복합체를 제조하는 방법.
  11. 생물부의 부족이나 기능부전으로 인해 발생되는 질병 치료용의 생물부의 생성을 위한 제1항 내지 9항 중 어느 한 항에 따른 활성물질 복합체의 용도.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920701038A 1989-11-03 1990-10-12 생유기체의 생물부, 특히 기관을 생성하기 위한 활성 물질 복합체, 이를 제조하는 방법 및 이의 용도 KR100195549B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE93936568.9 1989-11-03
DEP3936568.9 1989-11-03
DE3936568A DE3936568C2 (de) 1989-11-03 1989-11-03 Wirkstoffkomplex für die Herstellung von biologischen Teilen in Form von Organen für Lebewesen; Verfahren zum Herstellen desselben und seine Verwendung
PCT/DE1990/000782 WO1991006324A1 (de) 1989-11-03 1990-10-12 Wirkstoffkomplex für die herstellung von biologischen teilen, insbesondere von organen für lebewesen; verfahren zum herstellen desselben und seine verwendung

Publications (2)

Publication Number Publication Date
KR920703134A true KR920703134A (ko) 1992-12-17
KR100195549B1 KR100195549B1 (ko) 1999-06-15

Family

ID=6392769

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701038A KR100195549B1 (ko) 1989-11-03 1990-10-12 생유기체의 생물부, 특히 기관을 생성하기 위한 활성 물질 복합체, 이를 제조하는 방법 및 이의 용도

Country Status (12)

Country Link
US (1) US5932207A (ko)
EP (1) EP0500556B1 (ko)
JP (1) JP3626178B2 (ko)
KR (1) KR100195549B1 (ko)
AT (1) ATE188877T1 (ko)
BR (1) BR9007808A (ko)
DE (2) DE3936568C2 (ko)
DK (1) DK0500556T3 (ko)
ES (1) ES2142791T3 (ko)
GR (1) GR3032800T3 (ko)
RU (1) RU2093191C1 (ko)
WO (1) WO1991006324A1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
RU2121370C1 (ru) * 1992-04-11 1998-11-10 Шмидт Карлхайнц Способ получения активного комплекса биологического назначения
DE19917696A1 (de) * 1999-04-20 2000-10-26 Karlheinz Schmidt Mittel für die Herstellung biologischer Teile mit einem Wirkstoffkomplex und für diesen geeigneten Trägermaterialien
US7214654B1 (en) * 1994-12-07 2007-05-08 Karlheinz Schmidt Agent for the manufacture of biological parts including an active ingredient complex and carrying materials suitable for the active ingredient complex
US5928635A (en) * 1994-12-07 1999-07-27 Schmidt; Karlheinz Process for producing active agent complexes
US6989033B1 (en) 1992-09-17 2006-01-24 Karlheinz Schmidt Implant for recreating verterbrae and tubular bones
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
JP2002306518A (ja) * 2000-12-21 2002-10-22 Yuichi Mori 体内留置用具
US20020114795A1 (en) 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
KR100487693B1 (ko) * 2001-11-27 2005-05-06 (주)리젠메드 골아세포의 부착을 촉진하는 자연골 대체용 인공골 구조재료
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
US7556210B2 (en) * 2006-05-11 2009-07-07 S. C. Johnson & Son, Inc. Self-contained multi-sprayer
US7718616B2 (en) * 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8114428B2 (en) 2007-03-08 2012-02-14 Sbf Synthetic Bone Factory Gmbh Methods for manufacturing a composition for treating bone and/or cartilage defects
DE102007012276A1 (de) * 2007-03-08 2008-09-11 Sbf Synthetic Bone Factory Gmbh Zusammensetzung zur Behandlung von Knochen- und/oder Knorpeldefekten
AU2011329054B2 (en) 2010-11-15 2015-05-28 Zimmer Orthobiologics, Inc. Bone void fillers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2929144A1 (de) * 1979-07-19 1981-02-12 Behringwerke Ag Verfahren zur herstellung von kollagen
US4294753A (en) * 1980-08-04 1981-10-13 The Regents Of The University Of California Bone morphogenetic protein process
US4472840A (en) * 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
WO1984000540A1 (en) * 1982-08-04 1984-02-16 Jolla Cancer Res Found Polypeptide
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4932973A (en) * 1983-09-30 1990-06-12 El Gendler Cartilage and bone induction by artificially perforated organic bone matrix
IL74715A0 (en) * 1984-03-27 1985-06-30 Univ New Jersey Med Biodegradable matrix and methods for producing same
US4925924A (en) * 1984-03-27 1990-05-15 University Of Medicine And Dentistry Of New Jersey Biocompatible synthetic and collagen compositions having a dual-type porosity for treatment of wounds and pressure ulcers and therapeutic methods thereof
US4681763A (en) * 1985-06-11 1987-07-21 University Of Medicine And Dentistry Of New Jersey Composition for stimulating bone growth
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US4693718A (en) * 1985-10-31 1987-09-15 University Of Alabama In Birmingham Stimulation of chemotaxis by chemotactic peptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US5019087A (en) * 1986-10-06 1991-05-28 American Biomaterials Corporation Nerve regeneration conduit
US5154931A (en) * 1986-10-22 1992-10-13 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Growth-stimulating material derived from porcine bone therefor and a manufacturing process
US5041138A (en) * 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
DE3709101A1 (de) * 1987-03-20 1988-09-29 Mueller Lierheim Kg Biolog Lab Immobilisierungssubstanz
US4863732A (en) * 1987-12-16 1989-09-05 Collagen Corporation Injectable composition for inductive bone repair
GB2215209B (en) * 1988-03-14 1992-08-26 Osmed Inc Method and apparatus for biodegradable, osteogenic, bone graft substitute device
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
FR2637502A1 (fr) * 1988-10-12 1990-04-13 Duroselle Patrick Materiau de xenogreffe osseuse et procede d'obtention

Also Published As

Publication number Publication date
DE3936568C2 (de) 1997-06-19
ES2142791T3 (es) 2000-05-01
RU2093191C1 (ru) 1997-10-20
WO1991006324A1 (de) 1991-05-16
DE59010894D1 (de) 2000-02-24
ATE188877T1 (de) 2000-02-15
KR100195549B1 (ko) 1999-06-15
DE3936568A1 (de) 1991-05-08
BR9007808A (pt) 1992-09-29
JPH05501208A (ja) 1993-03-11
DK0500556T3 (da) 2000-05-22
JP3626178B2 (ja) 2005-03-02
GR3032800T3 (en) 2000-06-30
US5932207A (en) 1999-08-03
EP0500556B1 (de) 2000-01-19
EP0500556A1 (de) 1992-09-02

Similar Documents

Publication Publication Date Title
KR920703134A (ko) 생유기체의 생물부, 특히 기관을 생성하기 위한 활성물질 복합체, 이를 제조하는 방법 및 이의 용도
Ten Dijke et al. Growth factors for wound healing
Montesano et al. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing.
Grotendorst et al. EGF and TGF‐alpha are potent chemoattractants for endothelial cells and EGF‐like peptides are present at sites of tissue regeneration
KNIGHTON et al. Wound healing angiogenesis: indirect stimulation by basic fibroblast growth factor
DE69132918T2 (de) Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
Levine et al. Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair.
Clark et al. Platelet isoforms of platelet-derived growth factor stimulate fibroblasts to contract collagen matrices.
Hom et al. Angiogenic growth factors: their effects and potential in soft tissue wound healing
Chen et al. Polymeric growth factor delivery strategies for tissue engineering
US5693341A (en) Affinity bound collagen matrices for the delivery of biologically active agents
US5236704A (en) Controlled release formulation
RU2001133453A (ru) Композиции, содержащие кондиционированную клеточную культуральную среду, и способы их использования
DE69930155T2 (de) Spray verabreichung von zellen
Fournier et al. Biological molecule-impregnated polyester: an in vivo angiogenesis study
GB2146335A (en) Wound healing compositions
CN112538513B (zh) 细胞外基质mb生物蛋白及其制备试剂盒与方法
JP2510503B2 (ja) 脳由来細胞増殖因子
CN111172100A (zh) 一种控制细胞取向排列的生物3d打印方法
AU776260B2 (en) New humanized biomaterials, a process for their preparation and their applications
DE69316379T2 (de) Morphogeninduzierte regenerierung der leber
Albert et al. Stimulation in cell culture of mesenchymal cells of newt limb blastemas by EDGF I or II (basic or acidic FGF)
KR940005799A (ko) 거핵구 분화 인자
ES2057544T3 (es) Composiciones estabilizadas a base de fgf.
ATE366310T1 (de) Menschliches chondromodulin-i-protein

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090213

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee